Ovarian cancer: weekly dose-dense chemotherapy vs standard care


  • Dawn O'Shea
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Weekly dose-dense chemotherapy does not improve progression-free survival (PFS) compared with standard three-weekly chemotherapy, reports research published in the Lancet.

The phase 3 randomised controlled ICON8 trial compared the efficacy and safety of two dose-dense weekly regimens to standard three-weekly chemotherapy in women with newly diagnosed International Federation of Gynecology and Obstetrics stage IC-IV epithelial ovarian cancer. Patients entered the trial after immediate primary surgery or before neoadjuvant chemotherapy with subsequent planned delayed primary surgery.

A total of 1,566 participants (predominantly European) were randomised to receive carboplatin area under the curve (AUC)5 or AUC6 and 175 mg/m2 paclitaxel every three weeks (group 1), carboplatin AUC5 or AUC6 every three weeks and 80 mg/m2 paclitaxel weekly (group 2) and carboplatin AUC2 and 80 mg/m2 paclitaxel weekly (group 3).

Median PFS was 17.7 months (IQR 10.6-not reached) in group 1, 20.8 months (IQR 11.9-59.0) in group 2 and 21.0 months (95% CI 12.0-54.0) in group 3 (P=.35 for group 2 vs group 1; P=.51 for group 3 vs 1).

The authors concluded that although weekly dose-dense chemotherapy can be delivered successfully as first-line treatment for epithelial ovarian cancer, it does not significantly improve PFS compared with standard three-weekly chemotherapy in predominantly European populations.